We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

508 hedge funds and large institutions have $12.4B invested in Bio-Rad Laboratories Class A in 2021 Q2 according to their latest regulatory filings, with 61 funds opening new positions, 193 increasing their positions, 172 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 41

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 172

11% more capital invested

Capital invested by funds: $11.2B → $12.4B (+$1.18B)

3% more funds holding

Funds holding: 491508 (+17)

0.61% less ownership

Funds ownership: 79.25%78.65% (-0.61%)

49% less call options, than puts

Call options by funds: $39.6M | Put options by funds: $78.2M

Holders
508
Holders Change
+17
Holders Change %
+3.46%
% of All Funds
8.84%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.12%
New
61
Increased
193
Reduced
172
Closed
41
Calls
$39.6M
Puts
$78.2M
Net Calls
-$38.6M
Net Calls Change
-$47.3M
Name Holding Trade Value Shares
Change
Change in
Stake
HAG
301
HighPoint Advisor Group
Illinois
$736K +$90.7K +149 +15%
CC
302
Centiva Capital
New York
$724K +$460K +756 +205%
SP
303
Symmetry Partners
Connecticut
$718K -$79.7K -131 -11%
VIA
304
Vident Investment Advisory
Georgia
$708K -$40.8K -67 -6%
Assenagon Asset Management
305
Assenagon Asset Management
Luxembourg
$707K -$17.2M -28,273 -96%
P
306
Pitcairn
Pennsylvania
$706K -$449K -738 -40%
Bank Julius Baer & Co
307
Bank Julius Baer & Co
Switzerland
$705K +$498K +818 +296%
AP
308
Advisor Partners
California
$685K -$40.8K -67 -6%
Creative Planning
309
Creative Planning
Kansas
$682K -$12.8K -21 -2%
LMAM
310
Legg Mason Asset Management
Japan
$678K +$640K +1,052 New
QI
311
Qtron Investments
Massachusetts
$671K
ECM
312
Everence Capital Management
Indiana
$644K
FGAM
313
Financial Gravity Asset Management
Texas
$644K
TA
314
Tamarack Advisers
California
$644K +$609K +1,000 New
BDF
315
Balasa Dinverno & Foltz
$642K -$42K -69 -6%
MFGM
316
Marshall Financial Group (Maryland)
Maryland
$640K +$605K +994 New
ESCM
317
Echo Street Capital Management
New York
$633K +$302K +496 +102%
NMIMC
318
Northwestern Mutual Investment Management Company
Wisconsin
$631K +$2.43K +4 +0.4%
MAM
319
Meeder Asset Management
Ohio
$611K -$142K -234 -20%
Commonwealth Equity Services
320
Commonwealth Equity Services
Massachusetts
$598K +$68.8K +113 +14%
Bessemer Group
321
Bessemer Group
New Jersey
$575K -$28K -46 -5%
MG
322
Meritage Group
California
$561K +$86.4K +142 +19%
SG
323
Stonnington Group
California
$546K
CG
324
Colony Group
Massachusetts
$540K -$39K -64 -7%
PAG
325
Private Advisor Group
New Jersey
$538K +$509K +836 New

BIO Hedge Fund Activity: Q2 2021 in Review

508 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2021, worth a combined $12.4B — up 11% from $11.2B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new BIO positions and 41 closed out — a net gain of 20 holders — while 193 added to existing stakes and 172 trimmed.

The largest buyer was Franklin Resources, adding an estimated $66.6M. The largest seller was American Century Companies, cutting an estimated $246M.

  • 508 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2021, up from 491 in Q1 2021.
  • Funds reported $12.4B of Bio-Rad Laboratories Class A stock for Q2 2021, up 11% quarter-over-quarter.
  • 61 funds opened new Bio-Rad Laboratories Class A positions in Q2 2021 and 41 closed out, a net change of +20 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q2 2021 was Franklin Resources, an estimated $66.6M added.
  • The largest Bio-Rad Laboratories Class A seller in Q2 2021 was American Century Companies, an estimated $246M sold.

Based on aggregated 13F filings for Q2 2021.